217 related articles for article (PubMed ID: 30287427)
21. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
[TBL] [Abstract][Full Text] [Related]
22. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
Legendre P; Chahwan D; Marjanovic Z; Vignon M; Hermine O; Lortholary O; Morelle G; Darrodes M; Kahn JE; Ouzegdouh M; Chaibi P; Montestruc F; Caumont-Prim A; Le Jouan M; Hassani Y; Godeau B; Durand-Zaleski I; Mouthon L
Clin Immunol; 2020 Jun; 215():108419. PubMed ID: 32289463
[TBL] [Abstract][Full Text] [Related]
23. Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).
Syed MN; Kutac C; Miller JM; Marsh R; Sullivan KE; Cunningham-Rundles C; Fuleihan RL; Kheradmand F; Hajjar J
J Clin Immunol; 2022 Oct; 42(7):1545-1552. PubMed ID: 35779201
[TBL] [Abstract][Full Text] [Related]
24. The European internet-based patient and research database for primary immunodeficiencies: update 2011.
Gathmann B; Binder N; Ehl S; Kindle G;
Clin Exp Immunol; 2012 Mar; 167(3):479-91. PubMed ID: 22288591
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of patients with primary antibody deficiencies in Germany].
Borte M; Oertelt C; Högy B
Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive activities to increase recognition of primary immunodeficiency and access to immunoglobulin replacement therapy in Poland.
Pac M; Bernatowska E
Eur J Pediatr; 2016 Aug; 175(8):1099-105. PubMed ID: 27357411
[TBL] [Abstract][Full Text] [Related]
27. Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment.
Costa-Carvalho BT; Sullivan KE; Fontes PM; Aimé-Nobre F; Gonzales IGS; Lima ES; Granato C; de Moraes-Pinto MI
J Clin Immunol; 2018 Jul; 38(5):628-634. PubMed ID: 30006913
[TBL] [Abstract][Full Text] [Related]
28. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis.
Fu LW; Song C; Isaranuwatchai W; Betschel S
Ann Allergy Asthma Immunol; 2018 Feb; 120(2):195-199. PubMed ID: 29413344
[TBL] [Abstract][Full Text] [Related]
29. Humoral Immunodeficiency and Immune Globulin Replacement Therapy (IGRT) Usage in DiGeorge Syndrome.
Soshnick SH; Joseph T; Bennett NJ
J Clin Immunol; 2021 Aug; 41(6):1208-1212. PubMed ID: 33740168
[TBL] [Abstract][Full Text] [Related]
30. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
31. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?
Abolhassani H; Asgardoon MH; Rezaei N; Hammarstrom L; Aghamohammadi A
Expert Rev Clin Immunol; 2015; 11(11):1229-43. PubMed ID: 26289377
[TBL] [Abstract][Full Text] [Related]
32. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.
Jolles S; Chapel H; Litzman J
Clin Exp Immunol; 2017 Jun; 188(3):333-341. PubMed ID: 28000208
[TBL] [Abstract][Full Text] [Related]
33. Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.
Bienvenu B; Cozon G; Mataix Y; Lachaud D; Alix A; Hoarau C; Antier D; Hachulla E; Brice S; Viallard JF; Tamisier S; Fauchais AL; Renon-Carron F; Clerson P; Fardini Y; Crave JC; Miossec P
J Clin Immunol; 2018 May; 38(4):503-512. PubMed ID: 29855752
[TBL] [Abstract][Full Text] [Related]
34. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
35. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
[TBL] [Abstract][Full Text] [Related]
36. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
Patel V; Cowan J
Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
[TBL] [Abstract][Full Text] [Related]
37. [The Spanish Registry of Primary Immunodeficiencies (REDIP)].
Milá Llambí J; Etxagibel Galdos A; Matamoros Florí N
Allergol Immunopathol (Madr); 2001; 29(3):122-5. PubMed ID: 11434886
[TBL] [Abstract][Full Text] [Related]
38. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
Sriaroon P; Ballow M
Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
[TBL] [Abstract][Full Text] [Related]
40. 20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review.
Song J; Zhang L; Li Y; Quan S; Liang Y; Zeng L; Liu Y
Int Immunopharmacol; 2015 Apr; 25(2):457-64. PubMed ID: 25633961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
